Bank of America Corp DE Acquires 178,298 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Bank of America Corp DE increased its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 120,471.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 178,446 shares of the company's stock after buying an additional 178,298 shares during the period. Bank of America Corp DE owned 0.59% of TriSalus Life Sciences worth $894,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at about $67,000. Northern Trust Corp raised its position in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after buying an additional 5,936 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in TriSalus Life Sciences by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock worth $1,023,000 after buying an additional 3,710 shares during the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TLSI has been the topic of a number of research reports. Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a "buy" rating and a $10.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, TriSalus Life Sciences has an average rating of "Buy" and an average price target of $10.75.

TriSalus Life Sciences Trading Down 5.9%

TriSalus Life Sciences stock traded down $0.33 during mid-day trading on Wednesday, hitting $5.25. The stock had a trading volume of 40,871 shares, compared to its average volume of 42,323. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $6.18. The stock has a market capitalization of $198.65 million, a PE ratio of -2.11 and a beta of 0.47. The stock has a 50-day simple moving average of $5.40 and a two-hundred day simple moving average of $5.15.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the previous year, the company posted ($0.60) earnings per share. Sell-side analysts expect that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Transactions at TriSalus Life Sciences

In other news, insider Richard Marshak sold 6,597 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the sale, the insider now directly owns 69,101 shares of the company's stock, valued at $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 16,125 shares of company stock valued at $83,528. Corporate insiders own 27.50% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.